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On the role of IRS2 in the regulation of functional beta-cell mass
Abstract
The proper regulation of blood glucose homeostasis in mammals requires an adequate relation between
the capacity to produce insulin and metabolic demand. Insulin receptor substrate proteins (IRS) are
signalling intermediates that are required to keep this balance because they are needed for insulin action
in target tissues but also for insulin production in pancreatic beta-cells. The total functional beta-cell
mass in an individual sets the limit of how much insulin can be produced at a given time. It can change
adaptively to meet demand and studies in vivo indicate that the regulation of beta-cell mass involves
IRS2, while IRS1 is only required for proper insulin production in beta-cells. Overexpression studies in
isolated islets have shown that IRS2, but not IRS1 or Shc, is sufficient to induce proliferation of
beta-cells and to protect against d-glucose-induced apoptosis. In light of the finding that many growth
factors can regulate Irs2 in islets, this signalling intermediate could balance capacity for insulin
production with demand. This review summarizes observations in mouse models and in primary
beta-cells and proposes a new hypothetical model of how IRS2 might control beta-cell mass.
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Abstract 
The proper regulation of blood glucose homeostasis in mammals requires an adequate relation 
between the capacity to produce insulin and metabolic demand. Insulin receptor substrate 
proteins (IRS) are signalling intermediates that are required to keep this balance because they 
are needed for insulin action in target tissues but also for insulin production in pancreatic β-
cells. The total functional β-cell mass in an individual sets the limit of how much insulin can 
be produced at a given time. It can change adaptively to meet demand and studies in vivo 
indicate that the regulation of β-cell mass involves IRS2, while IRS1 is only required for 
proper insulin production in β-cells. Overexpression studies in isolated islets have shown that 
IRS2, but not IRS1 or Shc, is sufficient to induce proliferation of β-cells and to protect against 
D-glucose-induced apoptosis. In light of the finding that many growth factors can regulate 
Irs2 in islets, this signalling intermediate could balance capacity for insulin production with 
demand. This review summarizes observations in mouse models and in primary β-cells and 
proposes a new hypothetical model of how IRS2 might control β-cell mass.  
 
 
 
 
 
 
Keywords: Insulin receptor substrates, IRS2, diabetes, β-cell, proliferation, apoptosis. 
 
Abbreviations: PKB protein kinase B; FLIP Fas-associated death domain (FADD)-like 
interleukin-1β-converting enzyme (FLICE inhibitory protein); cAMP cyclic adenosine 
monophosphate; GFP green fluorescence protein; FFA free fatty acids. 
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1. Introduction 
 
Pancreatic β-cells are the only significant source of insulin in the body and total β-cell mass 
adapts to changes in insulin demand (Bonner-Weir 2001; Bonner-Weir 2000; Bonner-Weir et 
al. 1989). Importantly, compensatory expansion in functional β-cell mass can prevent the 
progression to overt hyperglycaemia during the pathogenesis of type 2 diabetes when 
increasing peripheral insulin resistance leads to an increasing demand for insulin (Kloppel et 
al. 1985). Eventually, however, the β-cells often fail to compensate and even recess in the 
face of chronic hyperglycaemia/hyperlipidemia which then results in diabetes.  
Increase in islet mass may occur via proliferation, cellular growth and/or reduced cell 
death. Indeed, a small fraction of adult β-cells is able to undergo cell division and can be 
recruited to re-enter the cell cycle (Montanya et al. 2000) and also changes in β-cell size 
(hypertrophy) have been reported (Jonas et al. 1999; Miyaura et al. 1991). On the other hand, 
a decrease in functional β-cell mass, as observed in the later stages of the pathogenesis of type 
2 diabetes, is believed to depend on apoptosis and to be induced by a combination of humoral 
and autocrine factors. It has been shown that e.g. chronically elevated concentrations of D-
glucose as well as increased concentrations of saturated free fatty acids (FFA) like palmitic 
acid induce β-cell apoptosis (Federici et al. 2001; Maedler et al. 2001a; Maedler et al. 2001b; 
Piro et al. 2002).  
Insulin receptor substrates (IRS) are evolutionarily conserved adapter proteins. They are 
required for many biological processes such as growth control, apoptosis, differentiation and 
regulation of fuel metabolism (Giovannone et al. 2000; Stocker and Hafen 2000). Mammals 
express four family members termed IRS1 to 4 although the human genome does not encode 
IRS3. The fruitfly Drosophila melanogaster expresses a single IRS homologue called chico 
(Bohni et al. 1999). IRS proteins link various membrane receptors to intracellular signalling 
pathways (Johnston et al. 2003; Kaburagi et al. 1999; White 1997) although their name 
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associates them solely with insulin signal transduction. Two domains at their NH2-terminus 
mediate receptor binding: a plextrin homology (PH) domain and a PTB region. While the 
PTB domain mediates interactions with phosphotyrosine residues in ligand-activated 
membrane receptors, the PH domain binds to phospholipids in the plasma membrane and 
probably not directly to receptors. IRS1 and IRS2 both contain numerous tyrosine-based 
motives some of which are phosphorylated upon binding to activated receptors. Once 
phosphorylated these sites can act as docking sites for downstream signalling molecules. On 
the other hand, serine/threonine phosphorylation of IRS proteins is believed to negatively 
influence their function and in some cases both types of phosphorylation seem to be mutually 
exclusive. As an example, tumour necrosis factor (TNFα) can stimulate phosphorylation of 
IRS1 at Ser307 (Kanety et al. 1995; Rui et al. 2002). This inhibits insulin-induced tyrosine 
phosphorylation of IRS1 and precedes its ubiquitination and proteolytic breakdown. Important 
downstream signalling components for IRS are e.g. the regulatory subunit of phosphatidyl 
inositol 3 kinase (PI3K/p85) and Grb2 that bind to IRS via src-homology (SH2) domains. IRS 
proteins do not contain a catalytic activity and they must therefore activate downstream 
targets by induction of conformational changes or by mediating the formation of activating 
complexes. Recruitment of p85 activates PI3K and induces phospholipid-dependent signalling 
resulting in the activation of protein kinase B (PKB). Binding of Grb2 links IRS-dependent 
signal transduction to the Ras/ERK1/2 pathway.  
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2. Mouse models show that Irs2 is required in islets for the regulation of 
blood glucose homeostasis 
 
How IRS proteins affect metabolic control has been extensively studied in knock out mice. 
Mice deficient for Irs1 (Araki et al. 1994; Tamemoto et al. 1994) are viable and fertile but 
retarded in embryonic and postnatal growth. They are resistant to insulin and IGF-I and 
display increased levels of fasting plasma insulin, however, these animals do not develop 
overt hyperglycaemia and diabetes due to islet hyperplasia. Irs1-deficient islets can adapt to 
insulin demand by proper regulation of apoptosis and proliferation after transplantation into 
hyperinsulinemic or normal backgrounds (Hennige et al. 2005). Nevertheless they manifest a 
secretory defect and reduced insulin production (Kulkarni et al. 1999b). All these results show 
that although Irs1 is required for insulin action and secretion from islets, its loss is not 
detrimental for the regulation of blood glucose homeostasis since β-cell compensation in the 
face of insulin resistance is not impaired. The opposite is true for Irs2-deficient mice. These 
animals are insulin resistant in liver, leptin resistant and develop overt diabetes at 3-6 weeks 
(Withers et al. 1998) or 10 weeks (Kubota et al. 2000) of age because of their inability to 
compensate the increased demand for insulin. Such mice are born with slightly reduced  islet 
mass and later show loss of β-cell mass and a reduction of insulin content indicating, that Irs2 
is essential for maintenance of β-cell mass and function. The study of two different strains of 
such Irs2-deficient mice clearly revealed a strong influence of genetic background on 
expressivity and penetrance (Terauchi et al. 2003) of the phenotype, but both of these studies 
pointed out that Irs2 was important for maintenance of liver insulin sensitivity. However, 
more recent work contradicts. Simmgen and coworkers. (Simmgen et al. 2006) eliminated 
Irs2 from the liver and describe only minimal abnormalities in glucose and lipid homeostasis 
and liver function.  
Hennige and co-workers (Hennige et al. 2003) generated transgenic mice that express 
IRS2 in β-cells under the control of the rat insulin II promotor (rip). When the transgene was 
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crossed into an Irs2-/- background, mice were rescued from diabetes indicating that Irs2 is 
autonomously required in β-cells. However, the rat insulin II promotor is not constitutively 
active in all β-cells besides also being activated in other cell types making it possible that 
expression of IRS2 in other cell types than β-cells rescued the mice from diabetes. Indeed, 
rip-CRE-based excision of floxed Irs2 to generate a β-cell-specific knockout reduced but did 
not completely eliminate expression from all β-cells and also resulted in loss of Irs2 
expression from the hypothalamus (Kubota et al. 2004; Lin et al. 2004). Metabolic control in 
these mice was never as severely perturbed as in the systemic Irs2 knockout and mice 
survived. They accumulated more fat, were leptin resistant and developed insulin resistance 
with increasing age. β-Cell mass was normal in younger (10 days or 4 week old) mice but 
reduced after 8 or 12 weeks. Surprisingly, at 6 months of age β-cell mass had recovered to 
normal levels and even increased over control with further age, presumably compensating for 
insulin resistance. The mild phenotype of hypothalamus- and β-cell-specific deletion of Irs2 
was therefore in part explained by β-cells escaping Cre-based excision (Lin et al. 2004) which 
prevented overt β-cell loss. Even a third study used rip-Cre to generate conditional Irs2 
knockout mice (Choudhury et al. 2005). Most results of the two previous studies were 
confirmed except for leptin resistance. Also this time β-cells still expressing IRS2 repopulated 
islets resulting in a mild phenotype without overt diabetes. By only eliminating Irs2 from 
brain but not from β-cells (NesCreIrs2KO and POMCCreIrs2KO) theses authors were able to 
show that β-cell loss is not caused by loss of Irs2 function in the hypothalamus. Finally, loss 
of Irs3 or Irs4 did not significantly affect glucose homeostasis (Fantin et al. 2000; Liu et al. 
1999) and will therefore not be discussed any further in this review.  
 
3. Overexpression of IRS2 in isolated islets is sufficient to increase β-cell 
proliferation and protects human β-cells from glucotoxicity  
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None of the mouse models had conclusively addressed the question if IRS2 function was also 
sufficient to autonomously regulate proliferation and apoptosis in β-cells. However, only if 
this was the case IRS2 would have a truly central role in the regulation of β-cell mass. To 
answer this question, we (Mohanty et al. 2005) decided to study β-cell proliferation and 
apoptosis in monolayer cultures of isolated islets (Kaiser et al. 1991). We determined the 
number of proliferating (Ki-67-positive) β-cells in rat islets after adenoviral overexpression of 
IRS2, IRS1, shc or GFP under the control of the cytomegalovirus (CMV) promoter. Our 
findings showed that high expression levels of IRS2, but not of IRS1 or Shc, can induce 
proliferation of β-cells outside of the context of the body (Figure 1A). This was clear 
evidence for a cell autonomous and instructive (and not only permissive) role of IRS2 in the 
control of β-cell proliferation. Nevertheless, the CMV promoter is active in many cell types 
and final proof for autonomy requires a transgene that directs IRS2 expression under a 
constitutive, β-cell-specific promoter. Remarkably, although IRS2 was overexpressed in all β-
cells after transfection of islets, not all β-cells entered the cell cycle. This could be due to a 
superimposed mechanism that limits the number of β-cells that can proliferate per islet and 
IRS2 did not override this control in our experimental system.  
Glucotoxicity manifests in human islets after culture in vitro for extended periods of time 
in the presence of high D-glucose by enhanced β-cell apoptosis and a reduced proliferation 
rate (Federici et al. 2001; Maedler et al. 2002b). Overexpression of IRS2 in human islets 
completely blocked the pro-apoptotic effect of chronic high D-glucose on human β-cells 
(Figure 1B). Moreover, human islets cultured for 3 days with 33.3 mM D-glucose and 
simultaneously overexpressing IRS2 displayed fewer apoptotic β-cells compared to islets that 
overexpressed IRS2 after culture under 5.5 mM D-glucose. This result suggests that IRS2 
could have a central role in human β-cells during the compensatory phase of the development 
of type 2 diabetes. High levels of IRS2 might not only prevent glucotoxicity in the face of 
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insulin resistance but could even trigger expansion of β-cell mass by reducing  β-cell 
apoptosis below basal levels. As for proliferation, neither overexpression of IRS1 nor of Shc 
could prevent D-glucose-induced apoptosis in human β-cells. Besides its effect on 
proliferation and apoptosis, overexpression of IRS2 but not of IRS1 increased basal and D-
glucose-induced insulin secretion in isolated rat islets indicating that IRS2 might also regulate 
insulin secretion from β-cells in vivo. 
How could overexpression of the adapter protein IRS2 that lacks any catalytic activity 
have an effect on β-cells? The medium for culturing islets in vitro contains foetal calf serum 
(FCS) and therefore many growth factors. An increased intracellular concentration of IRS2 
could simply enhance signal transduction downstream of their respective receptors that recruit 
IRS2 as a substrate resulting in more β-cell proliferation and less apoptosis. Experiments in 
INS-1 cells support this view which showed that overexression of IRS2 (but not of IRS1) 
increases proliferation induced by IGF1 and D-glucose (Lingohr et al. 2002b). However, we 
have observed that overexpression of IRS2 can activate PKB and increase 3H-thymidine 
incorporation in Chinese Hamster Ovary cells (CHO-IR), in the absence of growth factors 
under culture in starvation medium only containing 1 % Bovine Serum Albumin (Jaschinski 
et al, manuscript in preparation). Interestingly, also IRS1 but not Shc showed the same effect 
in CHO-IR stressing the importance of cellular context for the potency of the respective 
receptor substrate.  
 
4. Irs2 integrates many stimuli to control functional β-cell mass 
 
Since Irs2 is not only required but also sufficient for expansion of β-cell mass, its regulation 
downstream of growth factors could control islet mass. Many growth factors for β-cells have 
been identified (Lingohr et al. 2002a) and among them are hormones like insulin, IGF1/2, 
glucagon-like peptide (GLP)-1 and growth hormone (GH) but also nutrients like D-glucose. 
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We and others have shown that at least some of these factors can indeed increase expression 
levels and probably also the activity of IRS2 in β-cells. Second messengers such as cyclic 
AMP (cAMP) and Ca2+ appear to play a major role. GLP-1, D-glucose and other 
metabolisable hexoses increase transcription of Irs2 (Amacker-Francoys et al. 2005) by 
activation of cAMP response element-binding protein (CREB, Jhala et al. 2003). CREB can 
be activated by phosphorylation at serine 133 not only by cAMP-dependent protein kinase A 
(PKA) but also downstream of a number of other kinases such as protein kinase B (PKB/Akt), 
calmodulin-dependent protein kinases (CAM KII) and mitogen-activated protein kinase 
(MAPK, p44/42). Many growth factors activating these kinases might therefore regulate 
transcription of Irs2 via CREB. Indeed, insulin also increases IRS2 levels in β-cells, however, 
to a lesser extend and with a different kinetic compared to D-glucose (Amacker-Francoys et 
al. 2005). Culture of INS-1 cells at 16 mM D-glucose resulted in a sustained increase in IRS2 
levels compared to culture at 1.6 mM. Addition of insulin to INS-1 cells cultured at 1.6 mM 
D-glucose resulted in a transient and moderate increase in IRS2 levels, lasting only for several 
hours. Intriguingly, besides transcriptional activation, D-glucose also induced phosphorylation 
of IRS2, which was not observed for insulin. The regulation of Irs2 by D-glucose was not 
dependent on insulin secretion, since treatment with diazoxide to inhibit insulin secretion did 
neither prevent upregulation nor phosphorylation of IRS2 by D-glucose. D-glucose did not 
regulate the expression of Irs1 and therefore appears to control only the insulin receptor 
substrate that affects β-cell proliferation and apoptosis.  
Numerous studies have suggested that signal transduction through the insulin/IGF-
receptor pathways is involved in the regulation of β-cell mass and function (for review see 
Rhodes 2000). Insulin and insulin-like growth factor-1 (IGF-1) are growth factors for β-cells 
and their receptors use IRS proteins for signal transmission (Hugl et al. 1998). Mice lacking 
either the IR (βIRKO, (Kulkarni et al. 1999a) or IGF1R (βIGF1RKO, Kulkarni et al. 2002) in 
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β-cells have been generated. βIRKO mice lack first-phase insulin secretion in response to D-
glucose but not to arginine which resembles findings in humans early in the pathogenesis of 
type 2 diabetes where there is also a selective loss of acute phase insulin secretion. Islet size 
was moderately decreased in older βIRKO mice. Although such animals are progressively 
glucose intolerant starting from 2 month of age they never develop overt diabetes. Islets from 
βIGF1RKO mice also showed a glucose-specific defect in insulin secretion compared to 
controls but not defective islet growth. These studies therefore suggest that, although both 
insulin and IGF-1 can stimulate islet growth, their receptors are required for β-cell function 
but dispensable for maintenance of β-cell mass indicating that the regulation of β-cell size, 
proliferation and apoptosis is redundant and probably not dependent on signal transduction 
from a single growth factor receptor. 
Phosphorylation of IRS proteins at serine/threonine residues is believed to negatively 
regulate IRS-dependent signal transduction (reviewed by Pirola et al. 2004) in part depending 
on ubiquitination and proteosomal degradation. This mode of regulation might also operate in 
β-cells since Briaud and co-workers (Briaud et al. 2005) reported that chronic exposure of 
INS-1 cells to D-glucose induces mTOR-dependent Ser/Thr phosphorylation of IRS2 after 
only four hours which was accompanied by decreased IRS2 levels after 24 hours, decreased 
activation of PKB and an increase in apoptosis. Downregulation of IRS2 within 24 hours by 
D-glucose somewhat contrasts our own findings described above (Amacker-Francoys et al. 
2005). Although we also observed alkaline phosphatase-reversible modification of IRS2 
downstream of D-glucose within hours, upregulation of IRS2 persisted for at least 24 hours in 
our experiments. Despite this discrepancy the results nevertheless clearly demonstrate that D-
glucose is a potent regulator of IRS2 in β-cells.  
IRS2 protein levels might also be down regulated in β-cells under conditions of 
endoplasmic reticulum (ER) stress. The ER is known to play a pivotal role in β-cells, and ER-
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stress-dependent apoptosis in islets has been described in a number of studies (Araki et al. 
2003; Kaufman et al. 2002). The cellular response to ER-stress, called unfolded protein 
response (UPR, reviewed by Schroder and Kaufman 2005), has been shown to induce serine 
phosphorylation of IRS proteins in liver and fat via c-Jun N-terminal kinase (JNK) (Ozcan et 
al. 2004) and might therefore also suppress IRS2 in β-cells. Finally, FFA and cytokines like 
IL-1β can activate protein kinase C (PKC) isoforms, JNK and other stress kinases that 
suppress IRS2, thereby possibly leading to β-cell apoptosis.  
 
5. Pathways downstream of Irs2 
 
A great number of studies has been carried out to define the pathways controlling β-cell mass 
(reviewed by (Dickson and Rhodes 2004). Most of them used INS-1 cells (Asfari et al. 1992) 
which are slowly proliferating, D-glucose-sensitive, insulin-secreting cells that were derived 
from x-ray-induced rat insulinoma (Chick et al. 1977). Use of this permanent cell line greatly 
facilitates the analysis of the activation of signal transduction cascades because, unlike in 
lysates from isolated islets, many signalling intermediates are readily detectable in lysates 
from INS-1, not to speak from the availability of material for analysis. Results from these 
INS-1 studies indicate that the IRS2-PI3K-PKB (Hugl et al. 1998; Wang et al. 2004; Wrede et 
al. 2002) branch but not the Grb2-Ras-ERK1/2 module (Frodin et al. 1995) controls β-cell 
size, proliferation and apoptosis downstream of D-glucose/GLP-1/IGF/insulin. Without doubt, 
PKB is a central survival and growth factor in many cell types, however, deletion of PKB 
isoforms in mice has only minor effects on islet mass (reviewed by Yang et al. 2004)). pkbα-
deficient mice show impaired placental development and foetal growth (Chen et al. 2001; 
Tuttle et al. 2001; Yang et al. 2003) but no distortion in blood glucose homeostasis indicating 
normal islet growth and function. pkbβ-deficient mice were found to be insulin resistant, 
impaired in overall growth but displayed, dependent on strain and sex, compensatory increase 
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in β-cell mass (Cho et al. 2001; Garofalo et al. 2003). Finally, pkbγ-deficient mice merely 
displayed reduction in brain size without any metabolic distortions (Easton et al. 2005; 
Tschopp et al. 2005). Because the loss of each of the three known PKB isoforms did not 
(significantly) lead to an islet phenotype, by strict genetic definition, these kinases are not 
required for maintenance of islet mass in vivo in these models. Although there is of course the 
possibility that the two remaining isoforms could compensate for loss of one isoform such but 
compensation was not found in pkbγ-deficient mice (Tschopp et al. 2005). Furthermore, in 
another study β-cell-specific expression of a kinase-dead dominant-negative form of PKBα 
(rip-kdpkb) did also not reduce islet size, but resulted in defective insulin secretion (Bernal-
Mizrachi et al. 2004), also making compensation a less likely explanation for the observed 
phenotypes of PKB-deficient mice. In contrast to the loss of function phenotype, ectopic 
expression of constitutively active PKBα under the control of the rip promoter (Bernal-
Mizrachi et al. 2001; Tuttle et al. 2001) resulted in hypertrophy and hyperplasia of islets. Such 
mice were hyperinsulinaemic and resistant to streptozotocin-induced diabetes. Taken together 
the results from these mouse models suggest that although none of the PKB isoforms is 
required for maintenance of islet mass, constitutive activation of at least PKBα is sufficient to 
increase islet size. It is therefore tempting to speculate that maintenance and compensatory 
expansion of islet mass do not depend on the same signal transduction pathways downstream 
of IRS2.  
That IRS2 can control both, maintenance and expansion, follows from the observations 
that loss of IRS2 in islets results in β-cell loss while its overexpression can induce an increase 
in islet mass by increasing proliferation above and lowering the rate of apoptosis below basal 
levels (the latter in the presence of chronically high concentrations of D-glucose). On the 
other hand, overexpression of the caspase-8 inhibitor FLIP (Maedler et al. 2002a) also 
protects β-cells from the toxic effect of high glucose by reducing apoptosis and restoring 
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proliferation but only to basal levels, which should guarantee maintenance of islet mass, but is 
not expected to result in a compensatory increase. With this new concept in mind the 
phenotypes of βIRKO and βIGFRKO mice could be reinterpreted. Because these animals 
(like pkb-deficient mice) did not show significant growth defects in their islets the IGF1R and 
the IR might not be required for maintenance but could play a role in compensatory expansion 
of β-cell mass, maybe by IRS2-dependent activation of PKBα. The situation in vivo could 
still be more complex, since rip-kdpkb mice were found to increase their islet mass after high 
fat diet similar to controls, indicating that PKB could be dispensable even for expansion 
(Bernal-Mizrachi et al. 2004), however, expansion might have been driven by residual PKB 
activity. Furthermore, also in pkbβ knock out mice insulin resistance is compensated, at least 
in early stages, by compensatory increase in islet mass (Cho et al. 2001; Garofalo et al. 2003). 
It appears therefore that, although constitutive activation of PKBα in β-cells induces islet 
hyperplasia in mice, all evidence from the other studies rather contradicts the currently 
proposed model which positions PKB downstream of IRS2 in the overall control of β-cell 
mass. Overexpression of IRS2 in PKB-deficient islets followed by the analysis of 
proliferation and apoptosis could answer the question and we are currently performing these 
experiments.  
 
6. A hypothetical model describing the regulation of β-cell mass  
 
There is now good evidence to conclude that Irs2 is both necessary and sufficient to 
autonomously control the regulation of β-cell mass in rodents and probably also in humans. 
Irs2 integrates multiple redundant upstream inputs like nutrients, GLP-1, insulin, cytokines 
and FFA and thereby regulates islet mass in a context-specific manner. Especially the analysis 
of the phenotypes of PKB-deficient mice indicates that the pathways downstream of Irs2 are 
still not sufficiently defined in primary β-cells to describe how islet mass is maintained in the 
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healthy individual and expanded in the insulin resistant state during the pathogenesis of type 2 
diabetes. Maedler and co-workers proposed that β-cell survival, proliferation and function can 
be regulated by IL-1β-induced expression of the Fas receptor (Maedler et al. 2002b; Maedler 
et al. 2001b) dependent on expression levels of the caspase-8 inhibitor c-FLIP (Maedler et al. 
2002a). The hypothetical model depicted in figure 2 proposes that β-cell mass is regulated by 
negative cues emanating from receptors like Fas, and PKB-dependent signalling both under 
the control of Irs2. However, it postulates that the FLIP/Caspase-8 system solely affects 
maintenance of β-cell mass while expansion requires activation of PKBα leading to increased 
proliferation, cell growth and inhibition of the mitochondrial (caspase-9) pathway of 
apoptosis. It is well established that PKB can be activated downstream of IRS2 via PI3K, 
however, a link from IRS2 to FLIP is not obvious. A recent report (Chang et al. 2006) shows 
that c-FLIPL turnover is regulated by the E3 ubiquitin ligase Itch. JNK-dependent 
phosphorylation of Itch induces degradation of c-FLIPL and mediates TNFα-induced 
apoptosis. In β-cells, IRS2 could regulate the stability of c-FLIP to co-ordinate the rate of β-
cell apoptosis with actual metabolic demand. The model implies that extrinsic signals induce 
apoptosis to reduce β-cell mass in the absence of sufficient IRS2 activity. Nutrients and 
growth factors would counteract by increasing IRS2-levels and activity, e.g. leading to 
stabilization of c-FLIP, and keep β-cell mass constant. The model predicts that decreasing 
Fas-signalling should result in increased β-cell mass independent of metabolic demand. On 
the other hand, an increase in metabolic demand as under insulin resistance would activate 
PKB downstream of IRS2 protecting the β-cells against caspase-9 dependent apoptosis and 
increasing cell size and proliferation resulting in a compensatory increase in β-cell mass. It is 
the central theme of the model that Irs2 integrates many redundant stimuli and acts as a 
sensor/interpreter for intracellular and extracellular context to coordinate functional β-cell 
mass with the demand for insulin production.  
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7. Concluding remarks 
Many efforts to elucidate the role of IRS proteins in β-cells, to define the factors upstream and 
the pathways downstream that control β-cell apoptosis and proliferation were driven by the 
generally accepted adaptor concept underlying IRS function. As a result, the importance of 
the insulin/IGF-IRS2-PKB axis might have been overemphasized. The regulation of β-cell 
mass appears to be highly redundant, as suggested by the phenotype of insulin /IGF receptor 
and other knock out mouse models. β-Cells must be able to integrate many signals 
simultaneously, in order to properly match the capacity for insulin production with metabolic 
demand. It is now clear, that IRS2 is the perfect molecule for the job (Rhodes 2005). The 
molecular mechanisms underlying the regulation and function of IRS2 in β-cells will be 
central to understand how β-cell mass is regulated.  
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Figure legends 
 
 
Figure 1 
IRS2 can increase β-cell mass. (A) isolated rat islets were cultured on extra-cellular matrix 
(ECM)-coated plates, infected with adenoviral constructs encoding GFP, IRS1, IRS2 or Shc 
and stained for Ki-67 and insulin to visualize proliferating cells and β-cells, respectively. 
Overexpression of IRS2, but not of IRS1 or Shc, potently increased proliferation of β-cells 
compared to GFP. (B) human islets on ECM plates were cultured under 33.3 mM D-glucose 
for 48 hours to increase apoptosis. Overexpression of IRS2 repressed the rate of β-cell 
apoptosis below the level observed in control islets cultured at 5.5 mM D-glucose. 
Overexpression of IRS1 had no effect.  
Reprinted from Experimental Cell Research, 303, S. Mohanty et al. (2005), Overexpression of 
IRS2 in isolated pancreatic islets causes proliferation and protects human β-cells from 
hyperglycemia-induced apoptosis, Pages 68-78, Copyright (2004), with permission from 
Elsevier. 
 
Figure 2 
Hypothetical model describing how Irs2 could coordinate the regulation of β-cell mass with 
insulin/metabolic demand. It predicts that two different pathways control maintenance and 
compensatory expansion respectively, but that both are under the control of IRS2. To 
maintain β-cell mass, IRS2 increases the activity of molecules like c-FLIP to counteract the 
persistent negative influence of extrinsic signals acting through receptors like Fas that 
decrease proliferation, insulin production and increase apoptosis. Compensatory expansion of 
β-cell mass as observed under insulin resistance is predicted to depend on activation of PKB. 
PKB could prevent activation of caspase-9 by repression of the Bcl2 class of pro-apoptotic 
proteins in addition to its control over proliferation and cell growth. In this model IRS2 acts as 
a sensor/decoder for various positive and negative inputs making the regulation of β-cell mass 
highly redundant.  
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